3ded04dd的个人主页 - 老虎社区

3ded04dd

暂无个人介绍

IP属地：未知

40关注

2粉丝

0主题

0勋章

2021-12-27

[Like]

Japan Joins Coordinated Oil Sales to Combat Rising Prices<blockquote>日本加入协调石油销售以对抗价格上涨</blockquote>

2021-12-27

[Like]

BlackBerry is a Tough Buy That Will Test Investor Patience<blockquote>黑莓是一个艰难的买入，将考验投资者的耐心</blockquote>

2021-12-26

[Like]

抱歉，原内容已删除

2021-12-26

Time to chiong!

2021-12-25

Time to chiong!

2021-12-25

[Like] [Like]

COVID uptick to hurt MedTech firms and healthcare providers in early 2022 - Goldman Sachs<blockquote>2022年初，新冠疫情上升将损害医疗科技公司和医疗保健提供商——高盛</blockquote>

2021-12-23

Time to buy!

2021-12-23

👍

抱歉，原内容已删除

2021-08-27

💪

抱歉，原内容已删除

2021-08-27

💪

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4092415789566660","uuid":"4092415789566660","gmtCreate":1629313169644,"gmtModify":1640674332728,"name":"3ded04dd","pinyin":"siewdai","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":40,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":696909919,"gmtCreate":1640588287754,"gmtModify":1640588287846,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092415789566660","authorIdStr":"4092415789566660"},"themes":[],"htmlText":"[Like]&nbsp;","listText":"[Like]&nbsp;","text":"[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696909919","repostId":"1122841396","repostType":4,"repost":{"id":"1122841396","kind":"news","pubTimestamp":1640582377,"share":"https://www.laohu8.com/m/news/1122841396?lang=zh_CN&edition=full","pubTime":"2021-12-27 13:19","market":"fut","language":"en","title":"Japan Joins Coordinated Oil Sales to Combat Rising Prices<blockquote>日本加入协调石油销售以对抗价格上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122841396","media":"Bloomberg","summary":"(Bloomberg) -- Japan kicked off the sale of oil from its strategic reserves in a bid to combat risin","content":"<p>(Bloomberg) -- Japan kicked off the sale of oil from its strategic reserves in a bid to combat rising prices, joining an unprecedented coordinated release of crude from strategic stockpiles that’s been led by the U.S.</p><p><blockquote>（彭博社）--日本开始出售其战略储备中的石油，以应对油价上涨，加入了由美国领导的前所未有的协调释放战略储备原油的行列。</blockquote></p><p> A government tender offered Oman crude from the strategic reserves in Shibushi for delivery between March and June, the trade ministry said in a statement. The move is part of Japan’s plans to sell oil in coordination with other consuming nations and more sales may follow, according to a ministry official, who declined to be identified because of internal policy.</p><p><blockquote>贸易部在一份声明中表示，政府招标提供来自Shibushi战略储备的阿曼原油，将于3月至6月期间交付。一位因内部政策而拒绝透露姓名的日本政府官员表示，此举是日本与其他消费国协调销售石油计划的一部分，随后可能会有更多销售。</blockquote></p><p> The Biden administration started tapping the first of its pledged 50 million barrels of reserves not long after announcing the coordinated release in late November. South Korea said last week that it will start releasing crude and oil products from its strategic reserves next month, although other countries named as part of the plan -- including China and India -- have yet to act.</p><p><blockquote>拜登政府在11月底宣布协调释放后不久，就开始动用其承诺的5000万桶储备中的第一批。韩国上周表示，将于下月开始从战略储备中释放原油和石油产品，尽管被列为该计划一部分的其他国家——包括中国和印度——尚未采取行动。</blockquote></p><p> The inaugural volume offered by Japan is 100,000 kiloliters, according to a second ministry statement. The ministry plans to announce additional sales, while monitoring the energy markets, the official said.</p><p><blockquote>根据第二份外交部声明，日本提供的初始容量为10万千升。这位官员说，该部计划宣布额外的销售，同时监控能源市场。</blockquote></p><p> At present, there are signs of weakening oil demand in Asia given the rapid spread of the omicron variant of the coronavirus. Brent crude, the global benchmark, traded slightly higher above $76 a barrel on Monday, although it’s down by about 7% since the U.S.-led plan was announced.</p><p><blockquote>目前，鉴于新冠病毒奥密克戎变种的迅速传播，亚洲石油需求有减弱的迹象。全球基准布伦特原油周一略高于每桶76美元，尽管自美国主导的计划宣布以来已下跌约7%。</blockquote></p><p> Trade Minister Koichi Hagiuda said in November that Japan would conduct the release as it replaces oil in its stockpiles. While it does that regularly, the schedule has been moved up to support similar actions elsewhere, he added.</p><p><blockquote>贸易大臣萩生田光一(Koichi Hagiuda)去年11月表示，日本将在替换库存石油时进行释放。他补充说，虽然它经常这样做，但时间表已经提前，以支持其他地方的类似行动。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Japan Joins Coordinated Oil Sales to Combat Rising Prices<blockquote>日本加入协调石油销售以对抗价格上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJapan Joins Coordinated Oil Sales to Combat Rising Prices<blockquote>日本加入协调石油销售以对抗价格上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-12-27 13:19</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Japan kicked off the sale of oil from its strategic reserves in a bid to combat rising prices, joining an unprecedented coordinated release of crude from strategic stockpiles that’s been led by the U.S.</p><p><blockquote>（彭博社）--日本开始出售其战略储备中的石油，以应对油价上涨，加入了由美国领导的前所未有的协调释放战略储备原油的行列。</blockquote></p><p> A government tender offered Oman crude from the strategic reserves in Shibushi for delivery between March and June, the trade ministry said in a statement. The move is part of Japan’s plans to sell oil in coordination with other consuming nations and more sales may follow, according to a ministry official, who declined to be identified because of internal policy.</p><p><blockquote>贸易部在一份声明中表示，政府招标提供来自Shibushi战略储备的阿曼原油，将于3月至6月期间交付。一位因内部政策而拒绝透露姓名的日本政府官员表示，此举是日本与其他消费国协调销售石油计划的一部分，随后可能会有更多销售。</blockquote></p><p> The Biden administration started tapping the first of its pledged 50 million barrels of reserves not long after announcing the coordinated release in late November. South Korea said last week that it will start releasing crude and oil products from its strategic reserves next month, although other countries named as part of the plan -- including China and India -- have yet to act.</p><p><blockquote>拜登政府在11月底宣布协调释放后不久，就开始动用其承诺的5000万桶储备中的第一批。韩国上周表示，将于下月开始从战略储备中释放原油和石油产品，尽管被列为该计划一部分的其他国家——包括中国和印度——尚未采取行动。</blockquote></p><p> The inaugural volume offered by Japan is 100,000 kiloliters, according to a second ministry statement. The ministry plans to announce additional sales, while monitoring the energy markets, the official said.</p><p><blockquote>根据第二份外交部声明，日本提供的初始容量为10万千升。这位官员说，该部计划宣布额外的销售，同时监控能源市场。</blockquote></p><p> At present, there are signs of weakening oil demand in Asia given the rapid spread of the omicron variant of the coronavirus. Brent crude, the global benchmark, traded slightly higher above $76 a barrel on Monday, although it’s down by about 7% since the U.S.-led plan was announced.</p><p><blockquote>目前，鉴于新冠病毒奥密克戎变种的迅速传播，亚洲石油需求有减弱的迹象。全球基准布伦特原油周一略高于每桶76美元，尽管自美国主导的计划宣布以来已下跌约7%。</blockquote></p><p> Trade Minister Koichi Hagiuda said in November that Japan would conduct the release as it replaces oil in its stockpiles. While it does that regularly, the schedule has been moved up to support similar actions elsewhere, he added.</p><p><blockquote>贸易大臣萩生田光一(Koichi Hagiuda)去年11月表示，日本将在替换库存石油时进行释放。他补充说，虽然它经常这样做，但时间表已经提前，以支持其他地方的类似行动。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/japan-offers-oil-strategic-reserves-023254703.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/japan-offers-oil-strategic-reserves-023254703.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122841396","content_text":"(Bloomberg) -- Japan kicked off the sale of oil from its strategic reserves in a bid to combat rising prices, joining an unprecedented coordinated release of crude from strategic stockpiles that’s been led by the U.S.\nA government tender offered Oman crude from the strategic reserves in Shibushi for delivery between March and June, the trade ministry said in a statement. The move is part of Japan’s plans to sell oil in coordination with other consuming nations and more sales may follow, according to a ministry official, who declined to be identified because of internal policy.\nThe Biden administration started tapping the first of its pledged 50 million barrels of reserves not long after announcing the coordinated release in late November. South Korea said last week that it will start releasing crude and oil products from its strategic reserves next month, although other countries named as part of the plan -- including China and India -- have yet to act.\nThe inaugural volume offered by Japan is 100,000 kiloliters, according to a second ministry statement. The ministry plans to announce additional sales, while monitoring the energy markets, the official said.\nAt present, there are signs of weakening oil demand in Asia given the rapid spread of the omicron variant of the coronavirus. Brent crude, the global benchmark, traded slightly higher above $76 a barrel on Monday, although it’s down by about 7% since the U.S.-led plan was announced.\nTrade Minister Koichi Hagiuda said in November that Japan would conduct the release as it replaces oil in its stockpiles. While it does that regularly, the schedule has been moved up to support similar actions elsewhere, he added.","news_type":1,"symbols_score_info":{"BZmain":0.9,"CLmain":0.9}},"isVote":1,"tweetType":1,"viewCount":2859,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696900509,"gmtCreate":1640588226294,"gmtModify":1640588226423,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092415789566660","authorIdStr":"4092415789566660"},"themes":[],"htmlText":"[Like]&nbsp;","listText":"[Like]&nbsp;","text":"[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696900509","repostId":"1198596552","repostType":4,"repost":{"id":"1198596552","kind":"news","pubTimestamp":1640587950,"share":"https://www.laohu8.com/m/news/1198596552?lang=zh_CN&edition=full","pubTime":"2021-12-27 14:52","market":"us","language":"en","title":"BlackBerry is a Tough Buy That Will Test Investor Patience<blockquote>黑莓是一个艰难的买入，将考验投资者的耐心</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1198596552","media":"InvestorPlace","summary":"BB stock will be under pressure while revenue remains elusive","content":"<p><div> BlackBerry (NYSE:BB) has been under strong selling pressure in the last month. However, the meme stock is still up 38% year-to-date. But with BB stock down 8.9% in the last month and investors getting...</p><p><blockquote><div>黑莓（纽约证券交易所股票代码：BB）上个月一直面临强大的抛售压力。然而，该meme股票今年迄今仍上涨了38%。但随着BB股票上个月下跌8.9%，投资者...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/bb-stock-is-tough-buy-that-will-test-investor-patience/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/bb-stock-is-tough-buy-that-will-test-investor-patience/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BlackBerry is a Tough Buy That Will Test Investor Patience<blockquote>黑莓是一个艰难的买入，将考验投资者的耐心</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlackBerry is a Tough Buy That Will Test Investor Patience<blockquote>黑莓是一个艰难的买入，将考验投资者的耐心</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-27 14:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> BlackBerry (NYSE:BB) has been under strong selling pressure in the last month. However, the meme stock is still up 38% year-to-date. But with BB stock down 8.9% in the last month and investors getting...</p><p><blockquote><div>黑莓（纽约证券交易所股票代码：BB）上个月一直面临强大的抛售压力。然而，该meme股票今年迄今仍上涨了38%。但随着BB股票上个月下跌8.9%，投资者...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/bb-stock-is-tough-buy-that-will-test-investor-patience/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/bb-stock-is-tough-buy-that-will-test-investor-patience/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/bb-stock-is-tough-buy-that-will-test-investor-patience/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BB":"黑莓"},"source_url":"https://investorplace.com/2021/12/bb-stock-is-tough-buy-that-will-test-investor-patience/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198596552","content_text":"BlackBerry (NYSE:BB) has been under strong selling pressure in the last month. However, the meme stock is still up 38% year-to-date. But with BB stock down 8.9% in the last month and investors getting ready to turn the page on 2021, should speculative investors remain patient while BlackBerry’s business model comes to fruition?\nThat’s a tough ask, but that’s different from saying it’s impossible. Right now, BB stock has a couple of long-term catalysts. However, investors looking at its current fundamentals may be scared away.\nYear-over-year revenue for the company’s first two quarters is down 26%. Help could be on the way in the form of revenue that the company intends to receive by selling many of its mobile device patents.\nIt’s not surprising that BlackBerry is cutting ties from the namesake mobile device that made the company a household name. However, the emergence of the smartphone ended BlackBerry’s supremacy. Selling off the intellectual property will add some much needed revenue to the bottom-line.\nBut the deal has taken some time and based on recent price action, investors are losing patience. Nevertheless, when the company last reported earnings, Chief Executive Officer John Chen said there was an 80% chance that the sale would be completed by the quarter’s end, which will occur in February 2022.\nThe larger question, however, is how long investors will have to wait for the company’s other business units to deliver revenue.\nBlackBerry’s Future is Also Its Past\nI’ve always said I’m old enough to remember when the BlackBerry was a status symbol. But aside from being the precursor to our current smartphone addiction, many people loved the safety and security of their BlackBerry devices.\nThis focus on cybersecurity is not just part of BlackBerry’s past, but it’s also a key element of the company’s future. In fact, cybersecurity solutions from BlackBerry QNX accounts for nearly 66% of BlackBerry’s revenue. And the global cybersecurity market is expected to be valued at $345.4 billion by 2026. As it is currently valued at $183.34 billion, that’s an increase of around 88% in the next five years.\nThat’s not the only catalyst for BlackBerry. The company is also competing in the autonomous vehicle space with its Intelligent Vehicle Data Platform (IVY). This is a scalable, cloud-connected software program that BlackBerry is offering as a universal solution for connected vehicles. According to BlackBerry, the IVY system delivers on three key objectives.\nFirst, it accelerates development of “new in-vehicle customer experiences.” It also opens opportunities for connected vehicle manufacturers to expand their community of app developers. And it does all of that while streamlining costs.\nHowever, the real payoff for IVY won’t take place until automated vehicles become a reality. While analysts may disagree on the exact length of time for that to happen, it’s measured in years, not months.\nAnalysts Are Sending Mixed Messages\nThe consensus rating for BB stock is a Sell. However, analysts put the consensus 12-month price target for BlackBerry at $9.40. That’s a $7.67 upside. That means if there is a broader sell-off investors may want to consider buying BlackBerry at around $7.60.\nThat would be in-line with the stock’s most recent rating from Paul Treiber of the Royal Bank of Canada. On Dec. 17, Treiber gave the stock an Underperform rating with a $7.50 price target.\nHowever, after a sharp selloff, BB stock is presenting investors with a potentially bullish technical pattern that may allow the stock to move higher, particularly if it beats expectations when it reports earnings.\nCan BB Stock Get it Right?\nI don’t currently own BB stock, but it is one of the meme stocks that I find intriguing. That’s because its underlying business plan has potential. However, it’s likely to be several years before that potential is realized. For that reason, I’ll be keeping BlackBerry on my watch list, but I’ll be staying on the sidelines until I hear more.","news_type":1,"symbols_score_info":{"BB":0.9}},"isVote":1,"tweetType":1,"viewCount":2705,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698434101,"gmtCreate":1640488632226,"gmtModify":1640488632226,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092415789566660","authorIdStr":"4092415789566660"},"themes":[],"htmlText":"[Like]&nbsp;","listText":"[Like]&nbsp;","text":"[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698434101","repostId":"2193781141","repostType":4,"isVote":1,"tweetType":1,"viewCount":2671,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698434934,"gmtCreate":1640488567492,"gmtModify":1640488567492,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092415789566660","authorIdStr":"4092415789566660"},"themes":[],"htmlText":"Time to chiong!","listText":"Time to chiong!","text":"Time to chiong!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698434934","isVote":1,"tweetType":1,"viewCount":2691,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698226080,"gmtCreate":1640413636095,"gmtModify":1640413636095,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092415789566660","authorIdStr":"4092415789566660"},"themes":[],"htmlText":"Time to chiong!","listText":"Time to chiong!","text":"Time to chiong!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698226080","isVote":1,"tweetType":1,"viewCount":2611,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698228748,"gmtCreate":1640413587289,"gmtModify":1640413587358,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092415789566660","authorIdStr":"4092415789566660"},"themes":[],"htmlText":"[Like]&nbsp;[Like]&nbsp;","listText":"[Like]&nbsp;[Like]&nbsp;","text":"[Like] [Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698228748","repostId":"1198358760","repostType":4,"repost":{"id":"1198358760","kind":"news","pubTimestamp":1640396253,"share":"https://www.laohu8.com/m/news/1198358760?lang=zh_CN&edition=full","pubTime":"2021-12-25 09:37","market":"us","language":"en","title":"COVID uptick to hurt MedTech firms and healthcare providers in early 2022 - Goldman Sachs<blockquote>2022年初，新冠疫情上升将损害医疗科技公司和医疗保健提供商——高盛</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1198358760","media":"Seeking Alpha","summary":"The ongoing resurgence of the pandemic could limit recovery in hospital procedure volumes and delay ","content":"<p><ul>  <li>The ongoing resurgence of the pandemic could limit recovery in hospital procedure volumes and delay the rebound in MedTech procedures&nbsp;at least through early 2022, a team of analysts from Goldman Sachs argues.</p><p><blockquote><ul><li>高盛（Goldman Sachs）的一组分析师认为，疫情的持续卷土重来可能会限制医院手术量的恢复，并将医疗技术手术的反弹至少推迟到2022年初。</li></ul></blockquote></p><p></li>  <li>Issuing themes for portfolio set up in healthcare for 2022, the analysts led by Asad Haider warned last week that there could be at least one more COVID-19 wave with the rise of the Omicron variant of the virus.</li>  <li>Despite the uncertainty over a timeline for the “normalization,” the team sees potential for the disease to reach endemic status in the intermediate term, benefitting certain commercial firms and those leveraged on hospitals and procedures.</li>  <li>Focusing on the impact of such a scenario on utilization, the analysts turn their attention to MedTech, healthcare provision, and managed care.</li>  <li>According to them, the resurgence of COVID-19 cases could hurt procedure volumes in H1 2022 and worsen the nursing shortages, which in turn could result in a slowdown in elective procedures and limit the recovery in surgery volumes before subsiding in H2 2022.</li>  <li>“Expect relative underperformance to continue until at least the Spring, when a resetting of numbers and reduced hospital constraints could foster a recovery,” the analysts Amit Hazan and the team wrote. They predict that there could be more visibility by mid-2022 when “vaccines, natural immunity, antivirals and better overall management experience with Covid should increase the likelihood of recovery.”</li>  <li>Contrasting its projections in early 2021, the bank avoids modeling “MedTech procedure volumes to rebound to above pre-Covid trend due to pent-up demand or backlog.\" The analysts expect the companies to indicate this in their initial forecasts for next year implying further room for downward revisions in Street forecasts which, according to them, could be the last COVID-induced revision to MedTech estimates.</li>  <li>Goldman Sachs added Intuitive Surgical(NASDAQ:ISRG)to the firm’s conviction list, citing a potential launch of its multiport system in the first quarter. The maker of da Vinci Surgical System stands alongside Becton Dickinson(NYSE:BDX)and Zimmer Biomet(NYSE:ZBH)as a top large-cap pick in the space. However, the firm is less constructive on Stryker(NYSE:SYK), Medtronic(NYSE:MDT), Edwards Lifesciences(NYSE:EW), and Abbott(NYSE:ABT). See the graph below to compare how some of the above stocks have&nbsp;performed over the past year.</li>  <li>According to Seeking Alpha Quant Ratings, none of the large-cap MedTech companies, including Abbott (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), and Stryker (SYK), have Bullish prospects. The hospital operator HCA Healthcare(NYSE:HCA)is the only large-cap healthcare&nbsp;provider with a Bullish rating.</li>  <li>Meanwhile, Goldman Sachs cites a favorable backdrop in managed care space. Despite the ongoing limits to procedure volumes amid labor constraints and shift to low-cost settings, the companies in the subsector are conservatively priced, implying the return of deferred care and COVID costs, the analysts argue.</li> </ul></p><p><blockquote><li>以Asad Haider为首的分析师上周发布了2022年医疗保健投资组合的主题，警告称，随着病毒奥密克戎变种的兴起，可能至少还会出现一波COVID-19浪潮。</li><li>尽管“正常化”的时间表存在不确定性，但该团队认为该疾病有可能在中期内达到流行状态，使某些商业公司以及那些利用医院和程序的公司受益。</li><li>围绕这种情况对利用率的影响，分析师将注意力转向医疗技术、医疗保健提供和管理式医疗。</li><li>根据他们的说法，新冠肺炎病例的死灰复燃可能会损害2022年H1的手术量，并加剧护理短缺，这反过来可能会导致选择性手术放缓，并在2022年H2消退之前限制手术量的恢复。</li><li>分析师阿米特·哈赞(Amit Hazan)和团队写道：“预计相对表现不佳至少会持续到春季，届时人数的重置和医院限制的减少可能会促进经济复苏。”他们预测，到2022年中期，“疫苗、天然免疫、抗病毒药物和更好的新冠病毒整体管理经验应该会增加康复的可能性。”</li><li>与2021年初的预测相比，该银行避免模拟“由于被压抑的需求或积压，医疗技术手术量将反弹至高于新冠疫情前的趋势”。分析师预计，这些公司将在明年的初步预测中表明这一点，这意味着街头预测还有进一步下调的空间，据他们称，这可能是新冠疫情引发的对医疗技术预测的最后一次修正。</li><li>高盛将Intuitive Surgical（纳斯达克股票代码：ISRG）添加到该公司的定罪名单中，理由是其多端口系统可能会在第一季度推出。这家达芬奇手术系统制造商与Becton Dickinson(NYSE：BDX)和Zimmer Biomet(NYSE：ZBH)一起成为该领域的顶级大盘股。然而，该公司对史赛克(NYSE：SYK)、美敦力(NYSE：MDT)、爱德华兹生命科学(NYSE：EW)和雅培(NYSE：ABT)的建设性态度较差。请参阅下图，比较上述部分股票在过去一年的表现。</li><li>根据Seeking Alpha Quant Ratings的数据，包括雅培(ABT)、美敦力(MDT)、Intuitive Surgical(ISRG)和Stryker(SYK)在内的大型医疗科技公司都没有看涨的前景。医院运营商HCA Healthcare（纽约证券交易所股票代码：HCA）是唯一一家获得看涨评级的大型医疗保健提供商。</li><li>与此同时，高盛指出了管理式医疗领域的有利背景。分析师认为，尽管由于劳动力限制和向低成本环境的转变，手术量持续受到限制，但该子行业的公司定价保守，这意味着延期护理和新冠疫情成本的回归。</li></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID uptick to hurt MedTech firms and healthcare providers in early 2022 - Goldman Sachs<blockquote>2022年初，新冠疫情上升将损害医疗科技公司和医疗保健提供商——高盛</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID uptick to hurt MedTech firms and healthcare providers in early 2022 - Goldman Sachs<blockquote>2022年初，新冠疫情上升将损害医疗科技公司和医疗保健提供商——高盛</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-25 09:37</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>The ongoing resurgence of the pandemic could limit recovery in hospital procedure volumes and delay the rebound in MedTech procedures&nbsp;at least through early 2022, a team of analysts from Goldman Sachs argues.</p><p><blockquote><ul><li>高盛（Goldman Sachs）的一组分析师认为，疫情的持续卷土重来可能会限制医院手术量的恢复，并将医疗技术手术的反弹至少推迟到2022年初。</li></ul></blockquote></p><p></li>  <li>Issuing themes for portfolio set up in healthcare for 2022, the analysts led by Asad Haider warned last week that there could be at least one more COVID-19 wave with the rise of the Omicron variant of the virus.</li>  <li>Despite the uncertainty over a timeline for the “normalization,” the team sees potential for the disease to reach endemic status in the intermediate term, benefitting certain commercial firms and those leveraged on hospitals and procedures.</li>  <li>Focusing on the impact of such a scenario on utilization, the analysts turn their attention to MedTech, healthcare provision, and managed care.</li>  <li>According to them, the resurgence of COVID-19 cases could hurt procedure volumes in H1 2022 and worsen the nursing shortages, which in turn could result in a slowdown in elective procedures and limit the recovery in surgery volumes before subsiding in H2 2022.</li>  <li>“Expect relative underperformance to continue until at least the Spring, when a resetting of numbers and reduced hospital constraints could foster a recovery,” the analysts Amit Hazan and the team wrote. They predict that there could be more visibility by mid-2022 when “vaccines, natural immunity, antivirals and better overall management experience with Covid should increase the likelihood of recovery.”</li>  <li>Contrasting its projections in early 2021, the bank avoids modeling “MedTech procedure volumes to rebound to above pre-Covid trend due to pent-up demand or backlog.\" The analysts expect the companies to indicate this in their initial forecasts for next year implying further room for downward revisions in Street forecasts which, according to them, could be the last COVID-induced revision to MedTech estimates.</li>  <li>Goldman Sachs added Intuitive Surgical(NASDAQ:ISRG)to the firm’s conviction list, citing a potential launch of its multiport system in the first quarter. The maker of da Vinci Surgical System stands alongside Becton Dickinson(NYSE:BDX)and Zimmer Biomet(NYSE:ZBH)as a top large-cap pick in the space. However, the firm is less constructive on Stryker(NYSE:SYK), Medtronic(NYSE:MDT), Edwards Lifesciences(NYSE:EW), and Abbott(NYSE:ABT). See the graph below to compare how some of the above stocks have&nbsp;performed over the past year.</li>  <li>According to Seeking Alpha Quant Ratings, none of the large-cap MedTech companies, including Abbott (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), and Stryker (SYK), have Bullish prospects. The hospital operator HCA Healthcare(NYSE:HCA)is the only large-cap healthcare&nbsp;provider with a Bullish rating.</li>  <li>Meanwhile, Goldman Sachs cites a favorable backdrop in managed care space. Despite the ongoing limits to procedure volumes amid labor constraints and shift to low-cost settings, the companies in the subsector are conservatively priced, implying the return of deferred care and COVID costs, the analysts argue.</li> </ul></p><p><blockquote><li>以Asad Haider为首的分析师上周发布了2022年医疗保健投资组合的主题，警告称，随着病毒奥密克戎变种的兴起，可能至少还会出现一波COVID-19浪潮。</li><li>尽管“正常化”的时间表存在不确定性，但该团队认为该疾病有可能在中期内达到流行状态，使某些商业公司以及那些利用医院和程序的公司受益。</li><li>围绕这种情况对利用率的影响，分析师将注意力转向医疗技术、医疗保健提供和管理式医疗。</li><li>根据他们的说法，新冠肺炎病例的死灰复燃可能会损害2022年H1的手术量，并加剧护理短缺，这反过来可能会导致选择性手术放缓，并在2022年H2消退之前限制手术量的恢复。</li><li>分析师阿米特·哈赞(Amit Hazan)和团队写道：“预计相对表现不佳至少会持续到春季，届时人数的重置和医院限制的减少可能会促进经济复苏。”他们预测，到2022年中期，“疫苗、天然免疫、抗病毒药物和更好的新冠病毒整体管理经验应该会增加康复的可能性。”</li><li>与2021年初的预测相比，该银行避免模拟“由于被压抑的需求或积压，医疗技术手术量将反弹至高于新冠疫情前的趋势”。分析师预计，这些公司将在明年的初步预测中表明这一点，这意味着街头预测还有进一步下调的空间，据他们称，这可能是新冠疫情引发的对医疗技术预测的最后一次修正。</li><li>高盛将Intuitive Surgical（纳斯达克股票代码：ISRG）添加到该公司的定罪名单中，理由是其多端口系统可能会在第一季度推出。这家达芬奇手术系统制造商与Becton Dickinson(NYSE：BDX)和Zimmer Biomet(NYSE：ZBH)一起成为该领域的顶级大盘股。然而，该公司对史赛克(NYSE：SYK)、美敦力(NYSE：MDT)、爱德华兹生命科学(NYSE：EW)和雅培(NYSE：ABT)的建设性态度较差。请参阅下图，比较上述部分股票在过去一年的表现。</li><li>根据Seeking Alpha Quant Ratings的数据，包括雅培(ABT)、美敦力(MDT)、Intuitive Surgical(ISRG)和Stryker(SYK)在内的大型医疗科技公司都没有看涨的前景。医院运营商HCA Healthcare（纽约证券交易所股票代码：HCA）是唯一一家获得看涨评级的大型医疗保健提供商。</li><li>与此同时，高盛指出了管理式医疗领域的有利背景。分析师认为，尽管由于劳动力限制和向低成本环境的转变，手术量持续受到限制，但该子行业的公司定价保守，这意味着延期护理和新冠疫情成本的回归。</li></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3783326-covid-uptick-to-hurt-medtech-firms-and-healthcare-providers-in-early-2022-goldman-sachs\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GS":"高盛"},"source_url":"https://seekingalpha.com/news/3783326-covid-uptick-to-hurt-medtech-firms-and-healthcare-providers-in-early-2022-goldman-sachs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198358760","content_text":"The ongoing resurgence of the pandemic could limit recovery in hospital procedure volumes and delay the rebound in MedTech procedures at least through early 2022, a team of analysts from Goldman Sachs argues.\nIssuing themes for portfolio set up in healthcare for 2022, the analysts led by Asad Haider warned last week that there could be at least one more COVID-19 wave with the rise of the Omicron variant of the virus.\nDespite the uncertainty over a timeline for the “normalization,” the team sees potential for the disease to reach endemic status in the intermediate term, benefitting certain commercial firms and those leveraged on hospitals and procedures.\nFocusing on the impact of such a scenario on utilization, the analysts turn their attention to MedTech, healthcare provision, and managed care.\nAccording to them, the resurgence of COVID-19 cases could hurt procedure volumes in H1 2022 and worsen the nursing shortages, which in turn could result in a slowdown in elective procedures and limit the recovery in surgery volumes before subsiding in H2 2022.\n“Expect relative underperformance to continue until at least the Spring, when a resetting of numbers and reduced hospital constraints could foster a recovery,” the analysts Amit Hazan and the team wrote. They predict that there could be more visibility by mid-2022 when “vaccines, natural immunity, antivirals and better overall management experience with Covid should increase the likelihood of recovery.”\nContrasting its projections in early 2021, the bank avoids modeling “MedTech procedure volumes to rebound to above pre-Covid trend due to pent-up demand or backlog.\" The analysts expect the companies to indicate this in their initial forecasts for next year implying further room for downward revisions in Street forecasts which, according to them, could be the last COVID-induced revision to MedTech estimates.\nGoldman Sachs added Intuitive Surgical(NASDAQ:ISRG)to the firm’s conviction list, citing a potential launch of its multiport system in the first quarter. The maker of da Vinci Surgical System stands alongside Becton Dickinson(NYSE:BDX)and Zimmer Biomet(NYSE:ZBH)as a top large-cap pick in the space. However, the firm is less constructive on Stryker(NYSE:SYK), Medtronic(NYSE:MDT), Edwards Lifesciences(NYSE:EW), and Abbott(NYSE:ABT). See the graph below to compare how some of the above stocks have performed over the past year.\nAccording to Seeking Alpha Quant Ratings, none of the large-cap MedTech companies, including Abbott (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), and Stryker (SYK), have Bullish prospects. The hospital operator HCA Healthcare(NYSE:HCA)is the only large-cap healthcare provider with a Bullish rating.\nMeanwhile, Goldman Sachs cites a favorable backdrop in managed care space. Despite the ongoing limits to procedure volumes amid labor constraints and shift to low-cost settings, the companies in the subsector are conservatively priced, implying the return of deferred care and COVID costs, the analysts argue.","news_type":1,"symbols_score_info":{"GS":0.9}},"isVote":1,"tweetType":1,"viewCount":2111,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691218494,"gmtCreate":1640195245471,"gmtModify":1640195245471,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092415789566660","authorIdStr":"4092415789566660"},"themes":[],"htmlText":"Time to buy!","listText":"Time to buy!","text":"Time to buy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691218494","isVote":1,"tweetType":1,"viewCount":1964,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691218262,"gmtCreate":1640195197886,"gmtModify":1640195197886,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092415789566660","authorIdStr":"4092415789566660"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691218262","repostId":"2193194239","repostType":4,"isVote":1,"tweetType":1,"viewCount":2694,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":819184706,"gmtCreate":1630045214005,"gmtModify":1704955102931,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092415789566660","authorIdStr":"4092415789566660"},"themes":[],"htmlText":"💪","listText":"💪","text":"💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819184706","repostId":"2162010462","repostType":4,"isVote":1,"tweetType":1,"viewCount":1596,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819184568,"gmtCreate":1630045175354,"gmtModify":1704955102758,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092415789566660","authorIdStr":"4092415789566660"},"themes":[],"htmlText":"💪","listText":"💪","text":"💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819184568","repostId":"2162010462","repostType":4,"isVote":1,"tweetType":1,"viewCount":1356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":698434101,"gmtCreate":1640488632226,"gmtModify":1640488632226,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4092415789566660","idStr":"4092415789566660"},"themes":[],"htmlText":"[Like]&nbsp;","listText":"[Like]&nbsp;","text":"[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698434101","repostId":"2193781141","repostType":4,"isVote":1,"tweetType":1,"viewCount":2671,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696900509,"gmtCreate":1640588226294,"gmtModify":1640588226423,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4092415789566660","idStr":"4092415789566660"},"themes":[],"htmlText":"[Like]&nbsp;","listText":"[Like]&nbsp;","text":"[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696900509","repostId":"1198596552","repostType":4,"repost":{"id":"1198596552","kind":"news","pubTimestamp":1640587950,"share":"https://www.laohu8.com/m/news/1198596552?lang=zh_CN&edition=full","pubTime":"2021-12-27 14:52","market":"us","language":"en","title":"BlackBerry is a Tough Buy That Will Test Investor Patience<blockquote>黑莓是一个艰难的买入，将考验投资者的耐心</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1198596552","media":"InvestorPlace","summary":"BB stock will be under pressure while revenue remains elusive","content":"<p><div> BlackBerry (NYSE:BB) has been under strong selling pressure in the last month. However, the meme stock is still up 38% year-to-date. But with BB stock down 8.9% in the last month and investors getting...</p><p><blockquote><div>黑莓（纽约证券交易所股票代码：BB）上个月一直面临强大的抛售压力。然而，该meme股票今年迄今仍上涨了38%。但随着BB股票上个月下跌8.9%，投资者...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/bb-stock-is-tough-buy-that-will-test-investor-patience/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/bb-stock-is-tough-buy-that-will-test-investor-patience/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BlackBerry is a Tough Buy That Will Test Investor Patience<blockquote>黑莓是一个艰难的买入，将考验投资者的耐心</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlackBerry is a Tough Buy That Will Test Investor Patience<blockquote>黑莓是一个艰难的买入，将考验投资者的耐心</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-27 14:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> BlackBerry (NYSE:BB) has been under strong selling pressure in the last month. However, the meme stock is still up 38% year-to-date. But with BB stock down 8.9% in the last month and investors getting...</p><p><blockquote><div>黑莓（纽约证券交易所股票代码：BB）上个月一直面临强大的抛售压力。然而，该meme股票今年迄今仍上涨了38%。但随着BB股票上个月下跌8.9%，投资者...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/bb-stock-is-tough-buy-that-will-test-investor-patience/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/bb-stock-is-tough-buy-that-will-test-investor-patience/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/bb-stock-is-tough-buy-that-will-test-investor-patience/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BB":"黑莓"},"source_url":"https://investorplace.com/2021/12/bb-stock-is-tough-buy-that-will-test-investor-patience/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198596552","content_text":"BlackBerry (NYSE:BB) has been under strong selling pressure in the last month. However, the meme stock is still up 38% year-to-date. But with BB stock down 8.9% in the last month and investors getting ready to turn the page on 2021, should speculative investors remain patient while BlackBerry’s business model comes to fruition?\nThat’s a tough ask, but that’s different from saying it’s impossible. Right now, BB stock has a couple of long-term catalysts. However, investors looking at its current fundamentals may be scared away.\nYear-over-year revenue for the company’s first two quarters is down 26%. Help could be on the way in the form of revenue that the company intends to receive by selling many of its mobile device patents.\nIt’s not surprising that BlackBerry is cutting ties from the namesake mobile device that made the company a household name. However, the emergence of the smartphone ended BlackBerry’s supremacy. Selling off the intellectual property will add some much needed revenue to the bottom-line.\nBut the deal has taken some time and based on recent price action, investors are losing patience. Nevertheless, when the company last reported earnings, Chief Executive Officer John Chen said there was an 80% chance that the sale would be completed by the quarter’s end, which will occur in February 2022.\nThe larger question, however, is how long investors will have to wait for the company’s other business units to deliver revenue.\nBlackBerry’s Future is Also Its Past\nI’ve always said I’m old enough to remember when the BlackBerry was a status symbol. But aside from being the precursor to our current smartphone addiction, many people loved the safety and security of their BlackBerry devices.\nThis focus on cybersecurity is not just part of BlackBerry’s past, but it’s also a key element of the company’s future. In fact, cybersecurity solutions from BlackBerry QNX accounts for nearly 66% of BlackBerry’s revenue. And the global cybersecurity market is expected to be valued at $345.4 billion by 2026. As it is currently valued at $183.34 billion, that’s an increase of around 88% in the next five years.\nThat’s not the only catalyst for BlackBerry. The company is also competing in the autonomous vehicle space with its Intelligent Vehicle Data Platform (IVY). This is a scalable, cloud-connected software program that BlackBerry is offering as a universal solution for connected vehicles. According to BlackBerry, the IVY system delivers on three key objectives.\nFirst, it accelerates development of “new in-vehicle customer experiences.” It also opens opportunities for connected vehicle manufacturers to expand their community of app developers. And it does all of that while streamlining costs.\nHowever, the real payoff for IVY won’t take place until automated vehicles become a reality. While analysts may disagree on the exact length of time for that to happen, it’s measured in years, not months.\nAnalysts Are Sending Mixed Messages\nThe consensus rating for BB stock is a Sell. However, analysts put the consensus 12-month price target for BlackBerry at $9.40. That’s a $7.67 upside. That means if there is a broader sell-off investors may want to consider buying BlackBerry at around $7.60.\nThat would be in-line with the stock’s most recent rating from Paul Treiber of the Royal Bank of Canada. On Dec. 17, Treiber gave the stock an Underperform rating with a $7.50 price target.\nHowever, after a sharp selloff, BB stock is presenting investors with a potentially bullish technical pattern that may allow the stock to move higher, particularly if it beats expectations when it reports earnings.\nCan BB Stock Get it Right?\nI don’t currently own BB stock, but it is one of the meme stocks that I find intriguing. That’s because its underlying business plan has potential. However, it’s likely to be several years before that potential is realized. For that reason, I’ll be keeping BlackBerry on my watch list, but I’ll be staying on the sidelines until I hear more.","news_type":1,"symbols_score_info":{"BB":0.9}},"isVote":1,"tweetType":1,"viewCount":2705,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698228748,"gmtCreate":1640413587289,"gmtModify":1640413587358,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4092415789566660","idStr":"4092415789566660"},"themes":[],"htmlText":"[Like]&nbsp;[Like]&nbsp;","listText":"[Like]&nbsp;[Like]&nbsp;","text":"[Like] [Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698228748","repostId":"1198358760","repostType":4,"repost":{"id":"1198358760","kind":"news","pubTimestamp":1640396253,"share":"https://www.laohu8.com/m/news/1198358760?lang=zh_CN&edition=full","pubTime":"2021-12-25 09:37","market":"us","language":"en","title":"COVID uptick to hurt MedTech firms and healthcare providers in early 2022 - Goldman Sachs<blockquote>2022年初，新冠疫情上升将损害医疗科技公司和医疗保健提供商——高盛</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1198358760","media":"Seeking Alpha","summary":"The ongoing resurgence of the pandemic could limit recovery in hospital procedure volumes and delay ","content":"<p><ul>  <li>The ongoing resurgence of the pandemic could limit recovery in hospital procedure volumes and delay the rebound in MedTech procedures&nbsp;at least through early 2022, a team of analysts from Goldman Sachs argues.</p><p><blockquote><ul><li>高盛（Goldman Sachs）的一组分析师认为，疫情的持续卷土重来可能会限制医院手术量的恢复，并将医疗技术手术的反弹至少推迟到2022年初。</li></ul></blockquote></p><p></li>  <li>Issuing themes for portfolio set up in healthcare for 2022, the analysts led by Asad Haider warned last week that there could be at least one more COVID-19 wave with the rise of the Omicron variant of the virus.</li>  <li>Despite the uncertainty over a timeline for the “normalization,” the team sees potential for the disease to reach endemic status in the intermediate term, benefitting certain commercial firms and those leveraged on hospitals and procedures.</li>  <li>Focusing on the impact of such a scenario on utilization, the analysts turn their attention to MedTech, healthcare provision, and managed care.</li>  <li>According to them, the resurgence of COVID-19 cases could hurt procedure volumes in H1 2022 and worsen the nursing shortages, which in turn could result in a slowdown in elective procedures and limit the recovery in surgery volumes before subsiding in H2 2022.</li>  <li>“Expect relative underperformance to continue until at least the Spring, when a resetting of numbers and reduced hospital constraints could foster a recovery,” the analysts Amit Hazan and the team wrote. They predict that there could be more visibility by mid-2022 when “vaccines, natural immunity, antivirals and better overall management experience with Covid should increase the likelihood of recovery.”</li>  <li>Contrasting its projections in early 2021, the bank avoids modeling “MedTech procedure volumes to rebound to above pre-Covid trend due to pent-up demand or backlog.\" The analysts expect the companies to indicate this in their initial forecasts for next year implying further room for downward revisions in Street forecasts which, according to them, could be the last COVID-induced revision to MedTech estimates.</li>  <li>Goldman Sachs added Intuitive Surgical(NASDAQ:ISRG)to the firm’s conviction list, citing a potential launch of its multiport system in the first quarter. The maker of da Vinci Surgical System stands alongside Becton Dickinson(NYSE:BDX)and Zimmer Biomet(NYSE:ZBH)as a top large-cap pick in the space. However, the firm is less constructive on Stryker(NYSE:SYK), Medtronic(NYSE:MDT), Edwards Lifesciences(NYSE:EW), and Abbott(NYSE:ABT). See the graph below to compare how some of the above stocks have&nbsp;performed over the past year.</li>  <li>According to Seeking Alpha Quant Ratings, none of the large-cap MedTech companies, including Abbott (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), and Stryker (SYK), have Bullish prospects. The hospital operator HCA Healthcare(NYSE:HCA)is the only large-cap healthcare&nbsp;provider with a Bullish rating.</li>  <li>Meanwhile, Goldman Sachs cites a favorable backdrop in managed care space. Despite the ongoing limits to procedure volumes amid labor constraints and shift to low-cost settings, the companies in the subsector are conservatively priced, implying the return of deferred care and COVID costs, the analysts argue.</li> </ul></p><p><blockquote><li>以Asad Haider为首的分析师上周发布了2022年医疗保健投资组合的主题，警告称，随着病毒奥密克戎变种的兴起，可能至少还会出现一波COVID-19浪潮。</li><li>尽管“正常化”的时间表存在不确定性，但该团队认为该疾病有可能在中期内达到流行状态，使某些商业公司以及那些利用医院和程序的公司受益。</li><li>围绕这种情况对利用率的影响，分析师将注意力转向医疗技术、医疗保健提供和管理式医疗。</li><li>根据他们的说法，新冠肺炎病例的死灰复燃可能会损害2022年H1的手术量，并加剧护理短缺，这反过来可能会导致选择性手术放缓，并在2022年H2消退之前限制手术量的恢复。</li><li>分析师阿米特·哈赞(Amit Hazan)和团队写道：“预计相对表现不佳至少会持续到春季，届时人数的重置和医院限制的减少可能会促进经济复苏。”他们预测，到2022年中期，“疫苗、天然免疫、抗病毒药物和更好的新冠病毒整体管理经验应该会增加康复的可能性。”</li><li>与2021年初的预测相比，该银行避免模拟“由于被压抑的需求或积压，医疗技术手术量将反弹至高于新冠疫情前的趋势”。分析师预计，这些公司将在明年的初步预测中表明这一点，这意味着街头预测还有进一步下调的空间，据他们称，这可能是新冠疫情引发的对医疗技术预测的最后一次修正。</li><li>高盛将Intuitive Surgical（纳斯达克股票代码：ISRG）添加到该公司的定罪名单中，理由是其多端口系统可能会在第一季度推出。这家达芬奇手术系统制造商与Becton Dickinson(NYSE：BDX)和Zimmer Biomet(NYSE：ZBH)一起成为该领域的顶级大盘股。然而，该公司对史赛克(NYSE：SYK)、美敦力(NYSE：MDT)、爱德华兹生命科学(NYSE：EW)和雅培(NYSE：ABT)的建设性态度较差。请参阅下图，比较上述部分股票在过去一年的表现。</li><li>根据Seeking Alpha Quant Ratings的数据，包括雅培(ABT)、美敦力(MDT)、Intuitive Surgical(ISRG)和Stryker(SYK)在内的大型医疗科技公司都没有看涨的前景。医院运营商HCA Healthcare（纽约证券交易所股票代码：HCA）是唯一一家获得看涨评级的大型医疗保健提供商。</li><li>与此同时，高盛指出了管理式医疗领域的有利背景。分析师认为，尽管由于劳动力限制和向低成本环境的转变，手术量持续受到限制，但该子行业的公司定价保守，这意味着延期护理和新冠疫情成本的回归。</li></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID uptick to hurt MedTech firms and healthcare providers in early 2022 - Goldman Sachs<blockquote>2022年初，新冠疫情上升将损害医疗科技公司和医疗保健提供商——高盛</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID uptick to hurt MedTech firms and healthcare providers in early 2022 - Goldman Sachs<blockquote>2022年初，新冠疫情上升将损害医疗科技公司和医疗保健提供商——高盛</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-25 09:37</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>The ongoing resurgence of the pandemic could limit recovery in hospital procedure volumes and delay the rebound in MedTech procedures&nbsp;at least through early 2022, a team of analysts from Goldman Sachs argues.</p><p><blockquote><ul><li>高盛（Goldman Sachs）的一组分析师认为，疫情的持续卷土重来可能会限制医院手术量的恢复，并将医疗技术手术的反弹至少推迟到2022年初。</li></ul></blockquote></p><p></li>  <li>Issuing themes for portfolio set up in healthcare for 2022, the analysts led by Asad Haider warned last week that there could be at least one more COVID-19 wave with the rise of the Omicron variant of the virus.</li>  <li>Despite the uncertainty over a timeline for the “normalization,” the team sees potential for the disease to reach endemic status in the intermediate term, benefitting certain commercial firms and those leveraged on hospitals and procedures.</li>  <li>Focusing on the impact of such a scenario on utilization, the analysts turn their attention to MedTech, healthcare provision, and managed care.</li>  <li>According to them, the resurgence of COVID-19 cases could hurt procedure volumes in H1 2022 and worsen the nursing shortages, which in turn could result in a slowdown in elective procedures and limit the recovery in surgery volumes before subsiding in H2 2022.</li>  <li>“Expect relative underperformance to continue until at least the Spring, when a resetting of numbers and reduced hospital constraints could foster a recovery,” the analysts Amit Hazan and the team wrote. They predict that there could be more visibility by mid-2022 when “vaccines, natural immunity, antivirals and better overall management experience with Covid should increase the likelihood of recovery.”</li>  <li>Contrasting its projections in early 2021, the bank avoids modeling “MedTech procedure volumes to rebound to above pre-Covid trend due to pent-up demand or backlog.\" The analysts expect the companies to indicate this in their initial forecasts for next year implying further room for downward revisions in Street forecasts which, according to them, could be the last COVID-induced revision to MedTech estimates.</li>  <li>Goldman Sachs added Intuitive Surgical(NASDAQ:ISRG)to the firm’s conviction list, citing a potential launch of its multiport system in the first quarter. The maker of da Vinci Surgical System stands alongside Becton Dickinson(NYSE:BDX)and Zimmer Biomet(NYSE:ZBH)as a top large-cap pick in the space. However, the firm is less constructive on Stryker(NYSE:SYK), Medtronic(NYSE:MDT), Edwards Lifesciences(NYSE:EW), and Abbott(NYSE:ABT). See the graph below to compare how some of the above stocks have&nbsp;performed over the past year.</li>  <li>According to Seeking Alpha Quant Ratings, none of the large-cap MedTech companies, including Abbott (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), and Stryker (SYK), have Bullish prospects. The hospital operator HCA Healthcare(NYSE:HCA)is the only large-cap healthcare&nbsp;provider with a Bullish rating.</li>  <li>Meanwhile, Goldman Sachs cites a favorable backdrop in managed care space. Despite the ongoing limits to procedure volumes amid labor constraints and shift to low-cost settings, the companies in the subsector are conservatively priced, implying the return of deferred care and COVID costs, the analysts argue.</li> </ul></p><p><blockquote><li>以Asad Haider为首的分析师上周发布了2022年医疗保健投资组合的主题，警告称，随着病毒奥密克戎变种的兴起，可能至少还会出现一波COVID-19浪潮。</li><li>尽管“正常化”的时间表存在不确定性，但该团队认为该疾病有可能在中期内达到流行状态，使某些商业公司以及那些利用医院和程序的公司受益。</li><li>围绕这种情况对利用率的影响，分析师将注意力转向医疗技术、医疗保健提供和管理式医疗。</li><li>根据他们的说法，新冠肺炎病例的死灰复燃可能会损害2022年H1的手术量，并加剧护理短缺，这反过来可能会导致选择性手术放缓，并在2022年H2消退之前限制手术量的恢复。</li><li>分析师阿米特·哈赞(Amit Hazan)和团队写道：“预计相对表现不佳至少会持续到春季，届时人数的重置和医院限制的减少可能会促进经济复苏。”他们预测，到2022年中期，“疫苗、天然免疫、抗病毒药物和更好的新冠病毒整体管理经验应该会增加康复的可能性。”</li><li>与2021年初的预测相比，该银行避免模拟“由于被压抑的需求或积压，医疗技术手术量将反弹至高于新冠疫情前的趋势”。分析师预计，这些公司将在明年的初步预测中表明这一点，这意味着街头预测还有进一步下调的空间，据他们称，这可能是新冠疫情引发的对医疗技术预测的最后一次修正。</li><li>高盛将Intuitive Surgical（纳斯达克股票代码：ISRG）添加到该公司的定罪名单中，理由是其多端口系统可能会在第一季度推出。这家达芬奇手术系统制造商与Becton Dickinson(NYSE：BDX)和Zimmer Biomet(NYSE：ZBH)一起成为该领域的顶级大盘股。然而，该公司对史赛克(NYSE：SYK)、美敦力(NYSE：MDT)、爱德华兹生命科学(NYSE：EW)和雅培(NYSE：ABT)的建设性态度较差。请参阅下图，比较上述部分股票在过去一年的表现。</li><li>根据Seeking Alpha Quant Ratings的数据，包括雅培(ABT)、美敦力(MDT)、Intuitive Surgical(ISRG)和Stryker(SYK)在内的大型医疗科技公司都没有看涨的前景。医院运营商HCA Healthcare（纽约证券交易所股票代码：HCA）是唯一一家获得看涨评级的大型医疗保健提供商。</li><li>与此同时，高盛指出了管理式医疗领域的有利背景。分析师认为，尽管由于劳动力限制和向低成本环境的转变，手术量持续受到限制，但该子行业的公司定价保守，这意味着延期护理和新冠疫情成本的回归。</li></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3783326-covid-uptick-to-hurt-medtech-firms-and-healthcare-providers-in-early-2022-goldman-sachs\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GS":"高盛"},"source_url":"https://seekingalpha.com/news/3783326-covid-uptick-to-hurt-medtech-firms-and-healthcare-providers-in-early-2022-goldman-sachs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198358760","content_text":"The ongoing resurgence of the pandemic could limit recovery in hospital procedure volumes and delay the rebound in MedTech procedures at least through early 2022, a team of analysts from Goldman Sachs argues.\nIssuing themes for portfolio set up in healthcare for 2022, the analysts led by Asad Haider warned last week that there could be at least one more COVID-19 wave with the rise of the Omicron variant of the virus.\nDespite the uncertainty over a timeline for the “normalization,” the team sees potential for the disease to reach endemic status in the intermediate term, benefitting certain commercial firms and those leveraged on hospitals and procedures.\nFocusing on the impact of such a scenario on utilization, the analysts turn their attention to MedTech, healthcare provision, and managed care.\nAccording to them, the resurgence of COVID-19 cases could hurt procedure volumes in H1 2022 and worsen the nursing shortages, which in turn could result in a slowdown in elective procedures and limit the recovery in surgery volumes before subsiding in H2 2022.\n“Expect relative underperformance to continue until at least the Spring, when a resetting of numbers and reduced hospital constraints could foster a recovery,” the analysts Amit Hazan and the team wrote. They predict that there could be more visibility by mid-2022 when “vaccines, natural immunity, antivirals and better overall management experience with Covid should increase the likelihood of recovery.”\nContrasting its projections in early 2021, the bank avoids modeling “MedTech procedure volumes to rebound to above pre-Covid trend due to pent-up demand or backlog.\" The analysts expect the companies to indicate this in their initial forecasts for next year implying further room for downward revisions in Street forecasts which, according to them, could be the last COVID-induced revision to MedTech estimates.\nGoldman Sachs added Intuitive Surgical(NASDAQ:ISRG)to the firm’s conviction list, citing a potential launch of its multiport system in the first quarter. The maker of da Vinci Surgical System stands alongside Becton Dickinson(NYSE:BDX)and Zimmer Biomet(NYSE:ZBH)as a top large-cap pick in the space. However, the firm is less constructive on Stryker(NYSE:SYK), Medtronic(NYSE:MDT), Edwards Lifesciences(NYSE:EW), and Abbott(NYSE:ABT). See the graph below to compare how some of the above stocks have performed over the past year.\nAccording to Seeking Alpha Quant Ratings, none of the large-cap MedTech companies, including Abbott (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), and Stryker (SYK), have Bullish prospects. The hospital operator HCA Healthcare(NYSE:HCA)is the only large-cap healthcare provider with a Bullish rating.\nMeanwhile, Goldman Sachs cites a favorable backdrop in managed care space. Despite the ongoing limits to procedure volumes amid labor constraints and shift to low-cost settings, the companies in the subsector are conservatively priced, implying the return of deferred care and COVID costs, the analysts argue.","news_type":1,"symbols_score_info":{"GS":0.9}},"isVote":1,"tweetType":1,"viewCount":2111,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691218262,"gmtCreate":1640195197886,"gmtModify":1640195197886,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4092415789566660","idStr":"4092415789566660"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691218262","repostId":"2193194239","repostType":4,"isVote":1,"tweetType":1,"viewCount":2694,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696909919,"gmtCreate":1640588287754,"gmtModify":1640588287846,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4092415789566660","idStr":"4092415789566660"},"themes":[],"htmlText":"[Like]&nbsp;","listText":"[Like]&nbsp;","text":"[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696909919","repostId":"1122841396","repostType":4,"repost":{"id":"1122841396","kind":"news","pubTimestamp":1640582377,"share":"https://www.laohu8.com/m/news/1122841396?lang=zh_CN&edition=full","pubTime":"2021-12-27 13:19","market":"fut","language":"en","title":"Japan Joins Coordinated Oil Sales to Combat Rising Prices<blockquote>日本加入协调石油销售以对抗价格上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122841396","media":"Bloomberg","summary":"(Bloomberg) -- Japan kicked off the sale of oil from its strategic reserves in a bid to combat risin","content":"<p>(Bloomberg) -- Japan kicked off the sale of oil from its strategic reserves in a bid to combat rising prices, joining an unprecedented coordinated release of crude from strategic stockpiles that’s been led by the U.S.</p><p><blockquote>（彭博社）--日本开始出售其战略储备中的石油，以应对油价上涨，加入了由美国领导的前所未有的协调释放战略储备原油的行列。</blockquote></p><p> A government tender offered Oman crude from the strategic reserves in Shibushi for delivery between March and June, the trade ministry said in a statement. The move is part of Japan’s plans to sell oil in coordination with other consuming nations and more sales may follow, according to a ministry official, who declined to be identified because of internal policy.</p><p><blockquote>贸易部在一份声明中表示，政府招标提供来自Shibushi战略储备的阿曼原油，将于3月至6月期间交付。一位因内部政策而拒绝透露姓名的日本政府官员表示，此举是日本与其他消费国协调销售石油计划的一部分，随后可能会有更多销售。</blockquote></p><p> The Biden administration started tapping the first of its pledged 50 million barrels of reserves not long after announcing the coordinated release in late November. South Korea said last week that it will start releasing crude and oil products from its strategic reserves next month, although other countries named as part of the plan -- including China and India -- have yet to act.</p><p><blockquote>拜登政府在11月底宣布协调释放后不久，就开始动用其承诺的5000万桶储备中的第一批。韩国上周表示，将于下月开始从战略储备中释放原油和石油产品，尽管被列为该计划一部分的其他国家——包括中国和印度——尚未采取行动。</blockquote></p><p> The inaugural volume offered by Japan is 100,000 kiloliters, according to a second ministry statement. The ministry plans to announce additional sales, while monitoring the energy markets, the official said.</p><p><blockquote>根据第二份外交部声明，日本提供的初始容量为10万千升。这位官员说，该部计划宣布额外的销售，同时监控能源市场。</blockquote></p><p> At present, there are signs of weakening oil demand in Asia given the rapid spread of the omicron variant of the coronavirus. Brent crude, the global benchmark, traded slightly higher above $76 a barrel on Monday, although it’s down by about 7% since the U.S.-led plan was announced.</p><p><blockquote>目前，鉴于新冠病毒奥密克戎变种的迅速传播，亚洲石油需求有减弱的迹象。全球基准布伦特原油周一略高于每桶76美元，尽管自美国主导的计划宣布以来已下跌约7%。</blockquote></p><p> Trade Minister Koichi Hagiuda said in November that Japan would conduct the release as it replaces oil in its stockpiles. While it does that regularly, the schedule has been moved up to support similar actions elsewhere, he added.</p><p><blockquote>贸易大臣萩生田光一(Koichi Hagiuda)去年11月表示，日本将在替换库存石油时进行释放。他补充说，虽然它经常这样做，但时间表已经提前，以支持其他地方的类似行动。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Japan Joins Coordinated Oil Sales to Combat Rising Prices<blockquote>日本加入协调石油销售以对抗价格上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJapan Joins Coordinated Oil Sales to Combat Rising Prices<blockquote>日本加入协调石油销售以对抗价格上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-12-27 13:19</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Japan kicked off the sale of oil from its strategic reserves in a bid to combat rising prices, joining an unprecedented coordinated release of crude from strategic stockpiles that’s been led by the U.S.</p><p><blockquote>（彭博社）--日本开始出售其战略储备中的石油，以应对油价上涨，加入了由美国领导的前所未有的协调释放战略储备原油的行列。</blockquote></p><p> A government tender offered Oman crude from the strategic reserves in Shibushi for delivery between March and June, the trade ministry said in a statement. The move is part of Japan’s plans to sell oil in coordination with other consuming nations and more sales may follow, according to a ministry official, who declined to be identified because of internal policy.</p><p><blockquote>贸易部在一份声明中表示，政府招标提供来自Shibushi战略储备的阿曼原油，将于3月至6月期间交付。一位因内部政策而拒绝透露姓名的日本政府官员表示，此举是日本与其他消费国协调销售石油计划的一部分，随后可能会有更多销售。</blockquote></p><p> The Biden administration started tapping the first of its pledged 50 million barrels of reserves not long after announcing the coordinated release in late November. South Korea said last week that it will start releasing crude and oil products from its strategic reserves next month, although other countries named as part of the plan -- including China and India -- have yet to act.</p><p><blockquote>拜登政府在11月底宣布协调释放后不久，就开始动用其承诺的5000万桶储备中的第一批。韩国上周表示，将于下月开始从战略储备中释放原油和石油产品，尽管被列为该计划一部分的其他国家——包括中国和印度——尚未采取行动。</blockquote></p><p> The inaugural volume offered by Japan is 100,000 kiloliters, according to a second ministry statement. The ministry plans to announce additional sales, while monitoring the energy markets, the official said.</p><p><blockquote>根据第二份外交部声明，日本提供的初始容量为10万千升。这位官员说，该部计划宣布额外的销售，同时监控能源市场。</blockquote></p><p> At present, there are signs of weakening oil demand in Asia given the rapid spread of the omicron variant of the coronavirus. Brent crude, the global benchmark, traded slightly higher above $76 a barrel on Monday, although it’s down by about 7% since the U.S.-led plan was announced.</p><p><blockquote>目前，鉴于新冠病毒奥密克戎变种的迅速传播，亚洲石油需求有减弱的迹象。全球基准布伦特原油周一略高于每桶76美元，尽管自美国主导的计划宣布以来已下跌约7%。</blockquote></p><p> Trade Minister Koichi Hagiuda said in November that Japan would conduct the release as it replaces oil in its stockpiles. While it does that regularly, the schedule has been moved up to support similar actions elsewhere, he added.</p><p><blockquote>贸易大臣萩生田光一(Koichi Hagiuda)去年11月表示，日本将在替换库存石油时进行释放。他补充说，虽然它经常这样做，但时间表已经提前，以支持其他地方的类似行动。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/japan-offers-oil-strategic-reserves-023254703.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/japan-offers-oil-strategic-reserves-023254703.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122841396","content_text":"(Bloomberg) -- Japan kicked off the sale of oil from its strategic reserves in a bid to combat rising prices, joining an unprecedented coordinated release of crude from strategic stockpiles that’s been led by the U.S.\nA government tender offered Oman crude from the strategic reserves in Shibushi for delivery between March and June, the trade ministry said in a statement. The move is part of Japan’s plans to sell oil in coordination with other consuming nations and more sales may follow, according to a ministry official, who declined to be identified because of internal policy.\nThe Biden administration started tapping the first of its pledged 50 million barrels of reserves not long after announcing the coordinated release in late November. South Korea said last week that it will start releasing crude and oil products from its strategic reserves next month, although other countries named as part of the plan -- including China and India -- have yet to act.\nThe inaugural volume offered by Japan is 100,000 kiloliters, according to a second ministry statement. The ministry plans to announce additional sales, while monitoring the energy markets, the official said.\nAt present, there are signs of weakening oil demand in Asia given the rapid spread of the omicron variant of the coronavirus. Brent crude, the global benchmark, traded slightly higher above $76 a barrel on Monday, although it’s down by about 7% since the U.S.-led plan was announced.\nTrade Minister Koichi Hagiuda said in November that Japan would conduct the release as it replaces oil in its stockpiles. While it does that regularly, the schedule has been moved up to support similar actions elsewhere, he added.","news_type":1,"symbols_score_info":{"BZmain":0.9,"CLmain":0.9}},"isVote":1,"tweetType":1,"viewCount":2859,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698434934,"gmtCreate":1640488567492,"gmtModify":1640488567492,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4092415789566660","idStr":"4092415789566660"},"themes":[],"htmlText":"Time to chiong!","listText":"Time to chiong!","text":"Time to chiong!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698434934","isVote":1,"tweetType":1,"viewCount":2691,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698226080,"gmtCreate":1640413636095,"gmtModify":1640413636095,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4092415789566660","idStr":"4092415789566660"},"themes":[],"htmlText":"Time to chiong!","listText":"Time to chiong!","text":"Time to chiong!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698226080","isVote":1,"tweetType":1,"viewCount":2611,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691218494,"gmtCreate":1640195245471,"gmtModify":1640195245471,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4092415789566660","idStr":"4092415789566660"},"themes":[],"htmlText":"Time to buy!","listText":"Time to buy!","text":"Time to buy!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691218494","isVote":1,"tweetType":1,"viewCount":1964,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":819184706,"gmtCreate":1630045214005,"gmtModify":1704955102931,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4092415789566660","idStr":"4092415789566660"},"themes":[],"htmlText":"💪","listText":"💪","text":"💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819184706","repostId":"2162010462","repostType":4,"isVote":1,"tweetType":1,"viewCount":1596,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819184568,"gmtCreate":1630045175354,"gmtModify":1704955102758,"author":{"id":"4092415789566660","authorId":"4092415789566660","name":"3ded04dd","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4092415789566660","idStr":"4092415789566660"},"themes":[],"htmlText":"💪","listText":"💪","text":"💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819184568","repostId":"2162010462","repostType":4,"isVote":1,"tweetType":1,"viewCount":1356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}